Michael Rowbotham
Director/Miembro de la Junta en The University of California, San Francisco .
Perfil
Michael Rowbotham has been Chief Medical Officer of Adamas Pharmaceuticals, Inc. since June, 2006.
He is Professor of Neurology and a Director of the Pain Research Center and the Clinical Research, Ernest Gallo Clinic and Research Center at the University of California, San Francisco (UCSF).
Dr. Rowbotham received his BA degree in Biology from the University of California, San Diego and an MD from the University of California, San Francisco.
Cargos activos de Michael Rowbotham
| Empresas | Cargo | Inicio |
|---|---|---|
| The University of California, San Francisco | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Michael Rowbotham.
| Empresas | Cargo | Fin |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | - |
Formación de Michael Rowbotham.
| The University of California, San Francisco | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Michael Rowbotham
